SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

|The Artificial Superintelligence (ASI) Alliance is the world’s largest open-source initiative dedicated to decentralized Artificial General Intelligence (AGI). Formed in April 2024, the ASI Alliance unites SingularityNET, Fetch.ai, and Ocean Protocol, with CUDOS joining as a network member shortly after. The ASI Alliance was established through a community-approved tokenomic merger—combining $AGIX, $FET, and $OCEAN into a single token: $FET. This unified token underpins a collaborative framework designed to scale open-source AI and stand as the largest open-sourced, independent entity in AI research and development. The Alliance is committed to accelerating the advancement of decentralized Artificial General Intelligence (AGI) and, ultimately, Artificial Superintelligence (ASI). It provides a robust, open-source innovation stack, empowering developers, enterprises, and researchers globally to build ethical, scalable, and groundbreaking AI solutions. This ensures that advanced intelligence remains a shared, accessible resource, fostering innovation beyond centralized systems and promoting a future where AI benefits all.

Fetch.ai

Fetch.ai is experiencing significant volatility, with recent price dips generating both fear and strong accumulation sentiment among the community, exacerbated by controversial token actions from Ocean Protocol post-ASI alliance. Despite the FUD, many investors see current levels as a prime buying opportunity, citing Fetch.ai's ongoing development in the AI agent economy and its Google Cloud partnership as key drivers for long-term growth in the booming AI sector.

Codatta

XNY (Codatta) is a focal point of discussion following recent strong price action, including significant rallies that saw it outperform broader market pullbacks, leading many in the community to actively buy dips and anticipate further parabolic moves. While some warn of pump-and-dump characteristics, supporters are bullish on its potential as an AI data future project and its current technical strength.

London-based Quant Network is set to revolutionise blockchain technology with the development of their blockchain operating system Overledger. The experienced team are determined to fulfil the original vision of the internet by creating an open trusted network for people, machines, and data to operate securely and safely.  Overledger -the first interoperable blockchain operating system that facilitates internet-scale development of decentralised, multi-chain applications. Overledger has the ability to unlock and distribute value and applications across current and future blockchains. It is an agnostic platform that connects the world's networks to blockchains and ensures you're not limited to any single a vendor or technology. Overledger is the only platform that facilitates the development of internet-scales development of decentralised, multi-chain applications.

Quant

Quant (QNT) is trending as discussions surge around its Overledger technology being adopted for key initiatives like the UK's tokenized deposit pilot with major banks and the recent Quant Fusion launch, highlighting its role as essential infrastructure for connecting legacy financial systems with blockchain. The community is keenly focused on its perceived undervaluation, limited supply, and potential for massive institutional utility in the evolving digital economy.

CoStar Group, Inc. engages in the provision of online real estate marketplaces, information, and analytics in the commercial and residential property markets. It operates through the following segments: CoStar Portfolio, Information Services Portfolio, Multifamily Portfolio, LoopNet Portfolio, and Other Marketplaces Portfolio. The CoStar Portfolio segment consists of two classes of trade receivables based on geographical location: North America and International. The Information Services Portfolio segment includes four classes of trade receivables: CoStar Real Estate Manager, Hospitality, North America, Hospitality, International, and other Information Services. The Multifamily Portfolio, LoopNet Portfolio, and Other Marketplaces Portfolio segments focus on one class of trade receivables. The company was founded by Andrew C. Florance and Michael R. Klein in 1987 and is headquartered in Arlington, VA.

Costar Group, Inc.

CoStar Group is currently facing an activist campaign from Third Point, which is calling for a strategic reset and scrutinizing the significant investment in Homes.com. This has fueled community debate over the company's high valuation and residential growth initiatives, even as its core commercial real estate and Apartments.com businesses show strength amidst broader market challenges.

Endeavour Silver Corp. is a mineral company, which engages in the evaluation, acquisition, development and exploitation of precious metal properties in Mexico and Chile. The firm's projects include the Terronera property in Jalisco, the El Compas property, the Guanacevi Mine in Durango, Bolanitos Mines in Guanajuato, and the Parral project in Chihuahua, Mexico. The company was founded by Bradford James Cooke on March 11, 1981 and is headquartered in Vancouver, Canada.

Endeavour Silver Corp.

Endeavour Silver is gaining traction amid a significant silver price surge, driven by increasing industrial demand, concerns over physical supply tightness on COMEX, and news of China's impending silver export restrictions. The community is buzzing about the potential for silver miners, including EXK with its expanding production and strategic financing, to finally see a breakout that many believe has been suppressed by market manipulation.

Mama's Creations, Inc. engages in the marketing, manufacturing, and distribution of beef meatballs with sauce, turkey meatballs with sauce, beef meat loaf, sausage and peppers, chicken parmesan, and other similar meats and sauces. Its products include beef meatballs, turkey meatballs, stuffed meatballs, lasagna roll ups, retail ready meals, bulk deli, single-size pasta bowls, and packaged refrigerated products. Its brands include MamaMancini’s, Creative Salads, and The Olive Branch. The company was founded by Daniel Dougherty and Daniel Mancini on July 22, 2009 and is headquartered in East Rutherford, NJ.

Mama`s Creations Inc.

Mama's Creations is trending after delivering strong Q3 financial results that significantly beat expectations, fueled by robust revenue growth and the successful integration of its Crown I acquisition. The community is highly bullish, anticipating further market expansion and continued upside as the consumer products brand demonstrates strong operational traction and potential for long-term growth.

Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. Its proprietary in-house discovery platform, SNÅP, enables the rapid and precise refinement of structural design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA is developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR) family members, which are altered in approximately 7% of all cancers. The company was founded by Daniel Bensen and Todd Harris on August 2, 2018 and is headquartered in Carlsbad, CA.

Tyra Biosciences Inc

Tyra Biosciences is trending due to recent FDA clearance for its Phase 2 study of TYRA-300 in pediatric achondroplasia, alongside strong analyst coverage highlighting multi-billion-dollar potential for its precision FGFR3 inhibitor across oncology and rare disease indications. The community is actively discussing TYRA-300's "best-in-class" prospects and upcoming clinical catalysts anticipated to further de-risk the story.

ETF Series Solutions Trust - ESS U.S.Global Jets ETF

US Global Jets ETF

Amid record-breaking travel demand and falling jet fuel prices that are fueling optimism for airline earnings and technical breakouts, the JETS ETF is experiencing significant volatility from widespread flight cancellations due to severe winter storms and ongoing FAA operational issues. The community actively debates whether robust consumer enthusiasm and industry-specific tailwinds can consistently overcome external disruptions and regulatory pressures impacting the sector.

Peabody Energy Corp. engages in the business of coal mining. It operates through the following business segments: Seaborne Thermal, Seaborne Metallurgical, Powder River Basin, Other U.S. Thermal, and Corporate and Other. The Seaborne Thermal segment consist of mines in New South Wales, Australia. The Seaborne Metallurgical segment includes mines in Queensland, Australia, one in New South Wales, Australia and one in Alabama, USA. The Powder River Basin segment focuses on mines in Wyoming. The Other U.S. Thermal segment reflects on the mining, preparation and sale of thermal coal, sold primarily to electric utilities in the U.S. under long-term contracts, with a relatively small portion sold as international exports as conditions warrant. The Corporate and Other segment involves administrative expenses, results from equity method investments, trading and brokerage activities, minimum charges on certain transportation-related contracts, the closure of inactive mining sites, the impact of foreign currency remeasurement and certain commercial matters. The company was founded by Francis S. Peabody in 1883 and is headquartered in St. Louis, MO.

Peabody Energy Corp. - Ordinary Shares New

Peabody Energy is trending as the market responds to the Trump administration's new pro-coal policies, including directives for federal coal purchases and eased environmental regulations. Investors are also actively discussing the company's perceived undervaluation and the strategic upside from recent rare earth element discoveries within its coal assets.

LCX.com - Innovating Capital Markets. Solutions for compliant digital assets and security tokens. LCX is a secure and compliant platform for buying, selling, transferring, and storing digital currency.   LCX, the Liechtenstein Cryptoassets Exchange, was founded in 2018 with headquarters in Vaduz (Liechtenstein) and offices in Crypto-Valley Zug (Switzerland), New Delhi (India) and Chicago (USA). LCX has obtained 8 crypto-related registrations by the Financial Market Authority Liechtenstein, operates in accordance with the new blockchain laws and has introduced a comprehensive crypto compliance suite. LCX AG, the legal entity behind LCX.com, has a registered share capital of 1 Million CHF.  LCX is a proud member of the World Economic Forum's Centre for the Fourth Industrial Revolution and has been named Blockchain Pioneer by the Blockchain Research Institute Canada. The advisory board of LCX includes leading thought leader Don Tapscott (Author of Blockchain Revolution), Jimmy Wales (Founder of Wikipedia), Yat Siu (Chairman at Animoca Brands), and others.  In addition to LCX Exchange, LCX.com has launched a second layer DeFi protocol enabling limit orders at Uniswap (LCX DeFi Terminal), an advanced trading terminal for all major cryptocurrency exchanges (LCX Terminal), regulated price oracles and crypto reference prices, an  end to end tokenization platform for security tokens and a token sale manager for compliant initial coin offerings (ICO's and IEO's).   The LCX Token ($LCX) is the fuel of the LCX.com platform and LCX Cryptocurrency Exchange. LCX Token works as a long-term sustainable incentive mechanism to motivate various stakeholders to participate in the ecosystem. LCX Token is an exchange based utility token which grants all users a reduction of up to 50% trading fees at LCX’s compliant digital asset exchange and many more benefits.  More Information available at  www.LCX.com

LCX is trending with strong community focus on imminent MiCA regulatory approvals and the ongoing discussion around the "Clarity Act" for US market entry, positioning it as a compliant leader for institutional adoption and real-world asset tokenization. Investors are actively discussing its undervalued status and significant price appreciation potential as these anticipated regulatory milestones and a broader altcoin season are expected.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

C4 Therapeutics (CCCC) Projected to Post Quarterly Earnings on Thursday

C4 Therapeutics (NASDAQ:CCCC) will be releasing its Q4 2025 earnings before the market opens on Thursday, February 26. (View Earnings Report at...

C4 Therapeutics Maps Cemsidomide Phase II Launch, BCMA Combo Plans at Guggenheim Conference

C4 Therapeutics (NASDAQ:CCCC) executives outlined plans to advance their lead multiple myeloma program and expand the company's broader targeted protein degradation (TPD) platform during a fireside...

FY2028 EPS Forecast for C4 Therapeutics Reduced by Analyst

C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) - Stock analysts at Brookline Capital Management reduced their FY2028 earnings per share (EPS) estimates for shares of C4 Therapeutics in a report...

Leonard Reyno Sells 10,000 Shares of C4 Therapeutics (NASDAQ:CCCC) Stock

C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) insider Leonard Reyno sold 10,000 shares of the firm's stock in a transaction on Friday, January 16th. The shares were sold at an average price...

C4 Therapeutics, Inc. (NASDAQ:CCCC) Given Consensus Rating of "Moderate Buy" by Brokerages

Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) have earned a consensus rating of "Moderate Buy" from the nine research firms that are currently covering the firm, MarketBeat Ratings...

C4 Therapeutics, Inc. (NASDAQ:CCCC) Sees Significant Growth in Short Interest

C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) was the target of a large growth in short interest during the month of December. As of December 15th, there was short interest totaling 7,172,653...

C4 Therapeutics Target of Unusually High Options Trading (NASDAQ:CCCC)

C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) was the recipient of unusually large options trading activity on Wednesday. Stock investors bought 5,066 call options on the company. This is an...

C4 Therapeutics, Inc. (NASDAQ:CCCC) Given Average Recommendation of "Moderate Buy" by Brokerages

C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) has earned a consensus rating of "Moderate Buy" from the nine ratings firms that are presently covering the company, Marketbeat.com reports. One...

FY2028 EPS Estimates for C4 Therapeutics Lowered by Analyst

C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) - Investment analysts at Brookline Capital Management decreased their FY2028 EPS estimates for C4 Therapeutics in a report issued on Thursday...

C4 Therapeutics (NASDAQ:CCCC) Issues Quarterly Earnings Results

C4 Therapeutics (NASDAQ:CCCC - Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.44) EPS for the quarter, topping analysts' consensus estimates of ($0.47...

C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. It develops the Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Watertown, MA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.29	--	--	N/A
Q3 '25	-$0.41	-$0.44	-8.45%	MISSED
Q2 '25	-$0.38	-$0.37	3.65%	BEAT
Q1 '25	-$0.44	-$0.37	16.29%	BEAT
Q4 '24	-$0.49	-$0.49	0.62%	BEAT

CCCC
C4 Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest CCCC News

CCCCC4 Therapeutics Inc